Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Rating of “Moderate Buy” from Analysts

Precigen, Inc. (NASDAQ:PGEN) has been given an average rating of “Moderate Buy” by the five analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $7.00.

Separately, HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of Precigen in a report on Friday, November 15th.

Precigen Stock Performance

Shares of Precigen stock opened at $0.93 on Thursday. The company has a market cap of $272.37 million, a P/E ratio of -1.69 and a beta of 1.71. The firm has a fifty day moving average of $0.83 and a two-hundred day moving average of $1.11. Precigen has a one year low of $0.65 and a one year high of $1.93.

Institutional Trading of Precigen

A number of institutional investors have recently added to or reduced their stakes in the stock. Synovus Financial Corp lifted its position in shares of Precigen by 100.0% during the 3rd quarter. Synovus Financial Corp now owns 98,130 shares of the biotechnology company’s stock valued at $93,000 after acquiring an additional 49,065 shares during the period. Barclays PLC grew its holdings in shares of Precigen by 190.4% in the 3rd quarter. Barclays PLC now owns 189,353 shares of the biotechnology company’s stock worth $179,000 after acquiring an additional 124,141 shares during the period. Geode Capital Management LLC increased its stake in Precigen by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock valued at $3,075,000 after purchasing an additional 149,829 shares in the last quarter. State Street Corp raised its holdings in Precigen by 1.0% during the third quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock worth $2,720,000 after purchasing an additional 29,253 shares during the last quarter. Finally, Stifel Financial Corp boosted its position in Precigen by 94.9% during the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 15,680 shares in the last quarter. Hedge funds and other institutional investors own 33.51% of the company’s stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.